$MRVL · Marvell Technology, Inc.
Marvell Technology entered into a definitive merger agreement to acquire Lumentum Holdings in an all-stock transaction. Each Lumentum common share converts into 4.500 Marvell shares, with Lumentum Series A preferred holders able to elect Marvell Series B preferred instead. The deal includes a $5.8 billion Marvell termination fee, a $2.9 billion Lumentum termination fee, and a $3.2 billion regulatory termination fee, with an outside date of November 1, 2027 extendable to August 1, 2028 for regulatory delays.
- Marvell will issue 4.500 shares of its common stock for each share of Lumentum common stock.
- Marvell's board unanimously approved the deal; three Lumentum directors will join the Marvell board post-close.
- Marvell must pay a $5.8 billion termination fee if its board withdraws its recommendation or accepts a superior proposal.
- Lumentum faces a reciprocal $2.9 billion termination fee; a $3.2 billion regulatory termination fee applies to Marvell.
- The deal requires HSR clearance, stockholder approvals from both companies, and an S-4 registration statement.
MRVL dropped 10.05% in the regular session to $196.40, with extended-hours trading at $189.03 (-13.42% vs filing-time price), signaling the market is pricing in significant dilution and execution risk from this large-scale acquisition.
A $172B market-cap chip company acquiring a photonics peer in an all-stock deal with a $5.8B walk-away fee signals both strategic conviction and substantial antitrust risk that could stretch the timeline to mid-2028.
This deal extends the semiconductor consolidation wave into optical networking, pairing Marvell's data infrastructure silicon with Lumentum's photonics portfolio. The all-stock structure and massive termination fees suggest both parties view regulatory risk as the primary hurdle.
The $5.8 billion termination fee Marvell must pay if it walks away is unusually large and could deter competing bids. Regulatory risk is material — the Outside Date extends to August 1, 2028 if antitrust approvals are delayed, and a separate $3.2 billion regulatory termination fee applies if the deal fails on antitrust grounds.